Elshof Lotte E, Schaapveld Michael, Rutgers Emiel J, Schmidt Marjanka K, de Munck Linda, van Leeuwen Flora E, Wesseling Jelle
Division of Molecular Pathology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
Division of Psychosocial research and Epidemiology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
Breast Cancer Res. 2017 Mar 9;19(1):26. doi: 10.1186/s13058-017-0819-4.
Population screening with mammography has resulted in increased detection of ductal carcinoma in situ (DCIS). The aim of this population-based cohort study was to assess whether the method of detection should be considered when determining prognosis and treatment in women with DCIS.
This study includes 7042 women aged 49-75 years, who were surgically treated for primary DCIS between 1989 and 2004 in the Netherlands. We calculated cumulative incidences of ipsilateral and contralateral invasive breast cancer and all-cause mortality among women with screen-detected, interval, or non-screening-related DCIS, and assessed the association between method of detection and these outcomes, using multivariable Cox regression analyses.
Compared with non-screening-related DCIS, women with screen-detected DCIS had a lower risk of developing ipsilateral invasive breast cancer (hazard ratio (HR) = 0.75, 95% CI = 0.59-0.96), but a similar risk of contralateral invasive breast cancer (HR = 0.86, 95% CI = 0.67-1.10). The absolute difference in risk of ipsilateral invasive breast cancer was 1% at 15 years. Screen detection was associated with lower all-cause mortality (HR = 0.85, 95% CI = 0.73-0.98); when we additionally accounted for the occurrence of invasive breast cancer the magnitude of this effect remained similar (HR = 0.86, 95% CI = 0.75-1.00).
Screen detection was associated with lower risk of ipsilateral invasive breast cancer and all-cause mortality. However, the absolute difference in risk of ipsilateral invasive breast cancer was very low and the lower all-cause mortality associated with screen-detected and interval DCIS might be explained by a healthy-user effect. Therefore, our findings do not justify different treatment strategies for women with screen-detected, interval, or non-screening-related DCIS.
乳腺钼靶筛查已使导管原位癌(DCIS)的检出率增加。这项基于人群的队列研究旨在评估在确定DCIS女性的预后和治疗时,是否应考虑检测方法。
本研究纳入了1989年至2004年在荷兰因原发性DCIS接受手术治疗的7042名49 - 75岁女性。我们计算了筛查发现、间期或与筛查无关的DCIS女性同侧和对侧浸润性乳腺癌的累积发病率以及全因死亡率,并使用多变量Cox回归分析评估检测方法与这些结局之间的关联。
与非筛查相关的DCIS相比,筛查发现DCIS的女性发生同侧浸润性乳腺癌的风险较低(风险比(HR)= 0.75,95%置信区间(CI)= 0.59 - 0.96),但对侧浸润性乳腺癌的风险相似(HR = 0.86,95% CI = 0.67 - 1.10)。15年时同侧浸润性乳腺癌风险的绝对差异为1%。筛查发现与较低的全因死亡率相关(HR = 0.85,95% CI = 0.73 - 0.98);当我们进一步考虑浸润性乳腺癌的发生情况时,这种效应的大小仍然相似(HR = 0.86,95% CI = 0.75 - 1.00)。
筛查发现与较低的同侧浸润性乳腺癌风险和全因死亡率相关。然而,同侧浸润性乳腺癌风险的绝对差异非常小,且筛查发现和间期DCIS相关的较低全因死亡率可能由健康使用者效应来解释。因此,我们的研究结果并不支持对筛查发现、间期或与筛查无关的DCIS女性采取不同的治疗策略。